Teladoc Health (TDOC) Cash & Equivalents (2013 - 2026)

Teladoc Health's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $750.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 37.09% year-over-year to $750.7 million; the TTM figure through Mar 2026 stood at $750.7 million (down 37.09% YoY), while the FY2025 annual figure was $781.1 million, down 39.84% from the prior year.
• Cash & Equivalents came in at $750.7 million for Q1 2026 at Teladoc Health, down from $781.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q4 2024 to a low of $679.6 million in Q2 2025.
• A 5-year average of $968.8 million and a median of $918.2 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents climbed 23.56% in 2024 and tumbled 41.61% in 2025, its largest moves.
• Teladoc Health's Cash & Equivalents stood at $918.2 million in 2022, then rose by 22.38% to $1.1 billion in 2023, then climbed by 15.54% to $1.3 billion in 2024, then tumbled by 39.84% to $781.1 million in 2025, then fell by 3.89% to $750.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $750.7 million, $781.1 million, and $726.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison